438 related articles for article (PubMed ID: 28829992)
1. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.
Bascoul-Mollevi C; Gourgou S; Galais MP; Raoul JL; Bouché O; Douillard JY; Adenis A; Etienne PL; Juzyna B; Bedenne L; Conroy T
Eur J Cancer; 2017 Oct; 84():239-249. PubMed ID: 28829992
[TBL] [Abstract][Full Text] [Related]
2. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
Conroy T; Galais MP; Raoul JL; Bouché O; Gourgou-Bourgade S; Douillard JY; Etienne PL; Boige V; Martel-Lafay I; Michel P; Llacer-Moscardo C; François E; Créhange G; Abdelghani MB; Juzyna B; Bedenne L; Adenis A;
Lancet Oncol; 2014 Mar; 15(3):305-14. PubMed ID: 24556041
[TBL] [Abstract][Full Text] [Related]
3. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
Crosby T; Hurt CN; Falk S; Gollins S; Mukherjee S; Staffurth J; Ray R; Bashir N; Bridgewater JA; Geh JI; Cunningham D; Blazeby J; Roy R; Maughan T; Griffiths G
Lancet Oncol; 2013 Jun; 14(7):627-37. PubMed ID: 23623280
[TBL] [Abstract][Full Text] [Related]
4. Comparison of efficacy and toxicity profiles between paclitaxel/lobapoatin- and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer.
Yang JS; Wang T; Qiu MQ; Li QL
Intern Med J; 2015 Jul; 45(7):757-61. PubMed ID: 25851492
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer.
Hurmuzlu M; Aarstad HJ; Aarstad AK; Hjermstad MJ; Viste A
Dis Esophagus; 2011 Jan; 24(1):39-47. PubMed ID: 20819100
[TBL] [Abstract][Full Text] [Related]
7. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
[TBL] [Abstract][Full Text] [Related]
8. Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes.
McNamara MJ; Adelstein DJ; Allende DS; Bodmann JW; Ives DI; Murthy SC; Raymond D; Raja S; Rodriguez CP; Sohal D; Stephans KL; Videtic GMM; Rybicki LA
J Gastrointest Cancer; 2017 Jun; 48(2):181-189. PubMed ID: 27734205
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma.
Zhu HT; Ai DS; Tang HR; Badakhshi H; Fan JH; Deng JY; Zhang JH; Chen Y; Zhang Z; Xia Y; Guo XM; Jiang GL; Zhao KL
World J Gastroenterol; 2017 Jan; 23(3):540-546. PubMed ID: 28210091
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-related quality of life longitudinal analysis.
Bascoul-Mollevi C; Gourgou S; Borg C; Etienne PL; Rio E; Rullier E; Juzyna B; Castan F; Conroy T
Eur J Cancer; 2023 Jun; 186():151-165. PubMed ID: 37068407
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in a randomized trial of neoadjuvant chemotherapy or chemoradiotherapy plus surgery in patients with oesophageal cancer (NeoRes trial).
Sunde B; Klevebro F; Johar A; Johnsen G; Jacobsen AB; Glenjen NI; Friesland S; Lindblad M; Ajengui A; Lundell L; Lagergren P; Nilsson M
Br J Surg; 2019 Oct; 106(11):1452-1463. PubMed ID: 31436322
[TBL] [Abstract][Full Text] [Related]
13. Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial.
Noordman BJ; Verdam MGE; Lagarde SM; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch OR; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Spillenaar Bilgen EJ; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A; Sprangers MAG; van Lanschot JJB
J Clin Oncol; 2018 Jan; 36(3):268-275. PubMed ID: 29161204
[TBL] [Abstract][Full Text] [Related]
14. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer.
Conroy T; Yataghène Y; Etienne PL; Michel P; Senellart H; Raoul JL; Mineur L; Rives M; Mirabel X; Lamezec B; Rio E; Le Prisé E; Peiffert D; Adenis A
Br J Cancer; 2010 Oct; 103(9):1349-55. PubMed ID: 20940718
[TBL] [Abstract][Full Text] [Related]
15. Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma.
Kato K; Ito Y; Nozaki I; Daiko H; Kojima T; Yano M; Ueno M; Nakagawa S; Takagi M; Tsunoda S; Abe T; Nakamura T; Okada M; Toh Y; Shibuya Y; Yamamoto S; Katayama H; Nakamura K; Kitagawa Y;
Gastroenterology; 2021 Dec; 161(6):1878-1886.e2. PubMed ID: 34389340
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
[TBL] [Abstract][Full Text] [Related]
17. Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients.
Modesto A; Dalmasso C; Lusque A; Vieillevigne L; Izar F; Moyal E; Carrère N; Guimbaud R; Rives M
Cancer Radiother; 2020 Apr; 24(2):88-92. PubMed ID: 32156457
[TBL] [Abstract][Full Text] [Related]
18. Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX.
Lledo G; Huguet F; Chibaudel B; Di Fiore F; Mineur L; Galais MP; Artru P; Blondin V; Dupuis O; Abdiche MS; Jovenin N; Pozet A; Bonnetain F; Attia M; Dahan L; de Gramont A
Eur J Cancer; 2016 Mar; 56():115-121. PubMed ID: 26845174
[TBL] [Abstract][Full Text] [Related]
19. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.
DiSilvestro PA; Ali S; Craighead PS; Lucci JA; Lee YC; Cohn DE; Spirtos NM; Tewari KS; Muller C; Gajewski WH; Steinhoff MM; Monk BJ
J Clin Oncol; 2014 Feb; 32(5):458-64. PubMed ID: 24395863
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer.
Touchefeu Y; Archambeaud I; Landi B; Lièvre A; Lepère C; Rougier P; Mitry E
Dig Liver Dis; 2014 Mar; 46(3):283-6. PubMed ID: 24268567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
